IO-202 + Azacitidine/Venetoclax for AML and CMML
What You Need to Know Before You Apply
What is the purpose of this trial?
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
Who Is on the Research Team?
Hong Xiang, PhD
Principal Investigator
Immune-Onc Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults (18+) with certain types of blood cancer: relapsed or refractory Acute Myeloid Leukemia (AML) with specific differentiation, or Chronic Myelomonocytic Leukemia (CMML). Participants must have failed previous treatments and be in good enough health to give consent and undergo regular bone marrow/blood tests. Pregnant women, those with other severe illnesses, recent transplants, or known allergies to similar drugs cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive IO-202 monotherapy or IO-202 plus Azacitidine in ascending doses to assess safety and tolerability
Dose Expansion
Participants receive IO-202 plus Azacitidine ± Venetoclax to further evaluate safety and clinical activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Azacitidine
- IO-202
- Venetoclax
Azacitidine is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immune-Onc Therapeutics Inc
Lead Sponsor
Immune-Onc Therapeutics
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
Collaborator